San Antonio, Texas USA (UroToday.com) Heather Cheng, University of Washington, discussed BRCA and other DNA-repair genes in prostate cancer. All men with metastatic prostate cancer should be offered germline genetic testing.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Family cancer history (first/second degree, age of death, cause of death) is of upmost importance which may elucidate potential genetic mutations leading to carcinogenesis ie BRCA2 mutation carriers. Penetrance is defined at high, moderate and low with high being rare but leading to cancer phenotype. Germline BRCA2 mutations are inherited and can be passed to children at 50% and confer an autosomal dominant syndrome. BRCA2 mutation carriers with prostate cancer have been shown to have more aggressive disease. If a BRCA2 mutation is identified then other family members can be screened and counseled accordingly regarding BRCA2. Screening guidelines vary regarding genetic screening highlighting the need for further research discerning the clinical applicability and in who should screening be offered. The IMPACT study assessed prostate cancer screening in BRCA1/2 families with BRCA1/2 carries the incidence and positive predictive value and rate of intermediate/high risk prostate cancer is higher among carriers versus controls with final results pending.
Presented by: Heather Cheng, University of Washington
Written By: Stephen B. Williams, MD and Ashish M. Kamat
17th Annual Meeting of the Society of Urologic Oncology - November 30 -December 2, 2016 – San Antonio, Texas USA